As RNAi Efforts Advance, Merck Aims to Move siRNA Drug into the Clinic in 'One to Two Years' | GenomeWeb

By Doug Macron

While Merck has maintained a low profile regarding its RNAi activities since shelling out $1.1 billion to buy Sirna Therapeutics in early 2007, it continues to work in earnest on the gene-silencing technology and could begin testing an siRNA-based drug in humans as early as 2013, a company official said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.